crisantaspase porton biopharma
porton biopharma limited - irlanda - asparaginazum - pulb. pt. sol. inj./perf. - 10.000e - antineoplazice alte antineoplazice
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - leucemia limfoblastică limfoblastică a celulelor precursoare - agenți antineoplazici - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.